Summary
The parenteral infusion of lisuride in the treatment of fluctuations in complicated Parkinson’s disease is highly effective. We report about 18 patients, who were treated in our institutions. In our patient-group we observed a significant (p < 0.01) drop in the UPDRS—scores for rigor, akinesia and speech and for OFF-hours (− 30%), tremor remained nearly uneffected. Two deaths following myocardial infarction and pneumonia were not attributable to therapy. 6 patients experienced hallucinations, in 2 of these infusion had to be stopped. In 2 patients with drug-induced mental alterations these phenomena seemed to depend on the ratio of lisuride to levodopa as on the infusion-profile.
This new therapy is time-consuming and needs a highly individual approach, but remains most effective in the treatment of motor fluctuations and of dyskinesias, offering possibly even further insight into the pathogenesis of these phenomena.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Birkmayer W, Neumayer W (1972) Die Behandlung der DOPA-Psychosen mit L-Tryptophan. Der Nervenarzt 43 /2: 76 – 78
Birkmayer W, Riederer P (1975) Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post mortem findings). J Neural Transm 37: 175 – 182
Bittkau S, Przuntek W (1986) Psychosis and the lisuride pump. Lancet ii: 349 (letter)
Bittkau S, Przuntek H (1988) Chronic s. c. lisuride in parkinson’s diseasemotor performance and avoidance of psychiatric side effects. J Neural Transm [Suppl] 27: 35 – 54
Burns RS, Caine DB (1983) Disposition of dopaminergic ergot compounds following oral administration. In: Calne DB, et al (eds) Lisuride and other dopamine agonists. Raven Press, New York, pp 153 – 160
Celesia GG, Barr AN (1979) Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 23: 193 – 200
Critchley P, Grandas Perez F, Quinn N, Coleman R, Parkes D, Marsden CD (1986) Psychosis and the lisuride pump. Lancet ii: 349 (letter)
Critchley PHS, Grandas Perez F, Quinn N, Coleman R, Parkes D, Marsden CD (1988) Continuous subcutaneous lisuride infusions in Parkinson’s disease. J Neural Transm [Suppl] 27: 55 – 60
Fuxe K, Agnati LE, Köhler C, Andersson K, Eneroth P, Calza L, Ögren SO (1983) Heterogenity of brain dopamine systems: Possible discrimination of different types of dopamine systems and receptors by ergot drugs. In: Caine DB, Horowski R, Mc Donald RJ, Wittke W (eds) Lisuride and other dopamine-agonists. Raven Press, New York, pp 11 – 32
Gehlen W, Mü11er J (1974) Zur Therapie der Dopa-Psychosen mit L-Tryptophan. Dtsch Med Wochenschr 99: 457 – 463
Horowski R, Wachtel H (1976) Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. Eur J Pharmacol 36: 373 – 383
Hümpel M, Nieuweboer B, Wendt H, Hasan SH (1981) Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate: effects on plasma prolactin level. Eur J Clin Pharmacol 20: 47 – 51
Kehr W (1977) Effect of lisuride and other ergot derivatives on mono-aminergic mechanisms in rat brain. Eur J Pharmacol 41: 261 – 273
Klawans HL, Crosset P, Dana N (1975) Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of L-dopa-induced dyskinesias. In: Caine DB, Chase TN, Barbeau A (eds) Advances in Neurology, vol 9. Raven Press, New York
Lippem S (1976) Psychosis in patient on bromocriptine and levodopa with carbidopa. Lancet ii: 571
McDonald RJ, Horowski R (1983) Lisuride in the treatment of parkinsonism. Eur Neurol 240 – 255
Moskovitz C, Moses H, Klawans HL (1978) Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135: 669 – 675
Obeso JA, Luquin MR, Martinez Lage JM (1983) Lisuride infusion for Parkinson’s disease. Ann Neurol 14: 134
Obeso JA, Luquin MR, Martinez-Lage JM (1986) Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet is 467 – 470
Obeso JA, Luquin MR, Vaamonde J, Martinez Lage JM (1988) Subcutaneous administration of lisuride in the treatment of complex motor fluctuations in Parkinson’s disease. J Neural Transm [Suppl] 27: 17 – 25
Parkes JD, Schachter M, Marsden CD, Smith B, Wilson A (1981) Lisuride in parkinsonism. Ann Neurol 9: 48 – 52
Ponzio F, Cimino M, Achilli G, Lipartiti M, Perego C, Vantini G, Algeri S(1984) In vivo and in vitro evidence of dopaminergic system down regulation induced by chronic L-dopa. Life Sci 34: 2107–2116
Przuntek H (1988) Personal communication
Quinn N, Marsden CD, Schachter M, Thompson C, Lang AE, Parkes JD (1983) Intravenous lisuride in extrapyramidal disorders. Raven Press, pp 383 – 393
Reches A, Wagner HR, Jackson-Lewis V, Yablonskaya-Alter E, Fahn S (1984) Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum. Neurology 34: 1208–1212
Riederer P, Reanolds GP, Danielczyk W, Jellinger K, Seeman D (1983) Desensitization of striatal spiperone-binding sites by dopaminergic agonists in Parkinson’s disease. Raven Press, pp 375 – 381
Ruggieri S, Stocchi F, Agnoli A (1986) Lisuride infusion pump for Parkinson’s disease. Lancet ii: 348–349 (letter)
Schneider MB, Murrin LC, Pfeiffer RF, Deupree JD (1984) Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson’s disease. Clin Neuropharm 7 /3: 247 – 257
Shoulson I, Glaubiger GA, Chase TN (1975) On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25: 1144 – 1148
Shukla S, Turner WJ, Newman G (1978) Bromocriptin-related psychosis and treatment. Biol Psychiat 20: 305 – 310
Stocchi F, Ruggieri S, Antonini A, Baronti F, Brughitta G, Bellantuono P, Bravi D, Agnoli A (1988) Subcutaneous lisuride infusion in Parkinson’s disease: clinical results using different modes of administration. J Neural Transm [Suppl] 27: 27 – 33
Suchy I, Krause W (1988) Continuous subcutaneous infusion of lisuride in parkinsonian patients with fluctuations in mobility. De Gruytes (in press)
Sweet RD, Mc Dowell FH, Feigenson JS, Loranger AW, Goodell H (1976) Mental symptoms in Parkinson’s disease during chronic treatment with levodopa. Neurology 26: 30 – 310
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag/Wien
About this paper
Cite this paper
Bittkau, S., Klewin, I.R., Suchy, I., Przuntek, H. (1989). Continuous dopaminergic stimulation with parenteral lisuride in complicated Parkinson’s disease. In: Przuntek, H., Riederer, P. (eds) Early Diagnosis and Preventive Therapy in Parkinson’s Disease. Key Topics in Brain Research. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8994-8_42
Download citation
DOI: https://doi.org/10.1007/978-3-7091-8994-8_42
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82080-3
Online ISBN: 978-3-7091-8994-8
eBook Packages: Springer Book Archive